The mission of the MIT Center for Biomedical Innovation (CBI) is to improve global health by overcoming obstacles to the development and implementation of biomedical innovation. CBI provides a safe and transparent environment for collaborative research among academia, government, and industry, and draws on the expertise of the Massachusetts Institute of Technology (MIT) Schools of Engineering, Science, and Management, as well as the Harvard-MIT Division of Health Sciences and Technology (HST).

Biomanufacturing Program (BioMAN)
The BioMAN program is a forum for knowledge transfer between industry, government, and the academic community, focusing on industry studies and the development and execution of collaborative research and education in biomanufacturing. BioMAN’s working groups, workshops, and conferences bring together thought leaders from across the value chain including manufacturers, vendors, the government/FDA, and academia. BioMAN leverages both MIT and industrial expertise to create impactful educational experiences, to expand the reach of biomanufacturing education, and to better connect theoretical concepts to real-world application. BioMAN utilizes MIT research in both engineering and science to advance new technologies for bioprocessing and also draws on the economics, business strategy, and supply chain expertise at MIT to assess the impact of globalization of the industry and changes in biomanufacturing landscape.

Consortium on Adventitious Agent Contamination in Biomanufacturing (CAACB)
The CAACB Consortium focuses on mitigating the risk of adventitious agent contamination in biomanufacturing through collaborative research between MIT and 25 biopharmaceutical manufacturers and technology & service providers. The Consortium currently has four major projects including an industry-wide assessment of viral contamination experiences, an evaluation of the cost and effectiveness of media treatment options, identifying best practices in assessing viral contamination risk, and developing industry consensus on facility segregation approaches to viral safety. Each year, the CAACB also hosts two members-only workshops on topics such as “The Role of Testing in Control of Viral Contamination” and “The Science and Practice of Decontamination.”

NEW Drug Development ParaDIGmS (NEWDIGS)
MIT’s NEW Drug Development ParadIGmS (NEWDIGS) program is a unique collaborative “think and do” tank focused on enhancing the capacity of the global biomedical innovation system to reliably and sustainably deliver new, better, affordable therapeutics to the right patients faster. NEWDIGS provides a safe haven environment for designing, evaluating, and catalyzing meaningful high-impact advancements involving the coordinated evolution of technologies, processes, and policies that are so complex and cross-cutting they cannot be addressed by a single organization or market sector. Participants include global regulators, payers and health technology assessment officials, industry, patients, providers, and academic researchers, among other key stakeholders. The initial program area of NEWDIGS focused on catalyzing the evolution of global pharmaceutical regulation and helped to inspire the European Medicines Agency’s (EMA) adaptive pathways pilot program announced in March 2014.

The Massachusetts Life Sciences Center (MLSC) is a quasi-public agency of the Commonwealth of Massachusetts tasked with implementing the Massachusetts Life Sciences Act, a $1-billion initiative that was signed into law in June of 2008. The MLSC’s mission is to create jobs in the life sciences – biotechnology, pharmaceuticals, medical devices, diagnostics, and bioinformatics – and support vital scientific research that will improve the human condition. This work includes making financial investments in public and private institutions that are advancing life sciences research, development, and commercialization, as well as building ties among sectors of the Massachusetts life sciences community.